PMID- 37096834
OWN - NLM
STAT- MEDLINE
DCOM- 20231102
LR  - 20231102
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 22
IP  - 5
DP  - 2023 Jan-Jun
TI  - Safety considerations in the management of hepatitis C and HIV co-infection.
PG  - 363-372
LID - 10.1080/14740338.2023.2206647 [doi]
AB  - INTRODUCTION: Both HCV and HIV are highly prevalent infections with current 
      estimates of 57 and 38 million people infected worldwide, respectively. Oral 
      antivirals can be curative for HCV and rescue HIV patients from disease 
      progression. Dual therapy in coinfected patients requires expertise. AREAS 
      COVERED: Four major issues challenge dual HCV and HIV treatment, including 
      overlapping drug-related side effects, hepatitis B reactivation, immune 
      reconstitution inflammatory syndromes (IRIS), and drug-drug interactions (DDI). A 
      search was conducted in PubMed from January 2010 to March 2023. EXPERT OPINION: 
      The advent of second-generation direct-acting antivirals (DDA) that depict higher 
      antiviral potency, fewer side effects, pangenotypic activity and are 
      co-formulated has expanded the indication of HCV therapy and particularly in 
      HIV-coinfected individuals. Sequential initiation of antiretrovirals (ARV) 
      followed by DAA is generally preferred to start dual treatment concomitantly. 
      Close monitoring of rare episodes of HBV reactivation and IRIS is warranted. The 
      most frequent DDI between DAA and ARV affect drug metabolism by CYP450 
      induction/inhibition, leading to abnormal drug exposures. Throughout this 
      mechanism interact most HCV and HIV protease inhibitors and non-nucleoside 
      polymerase inhibitors. Exposure to some HIV and HCV nucleos(t)ide analogues (e.g. 
      tenofovir and sofosbuvir, respectively) is subject to induction/inhibition of 
      drug transporters and requires special attention in patients with renal 
      insufficiency.
FAU - Soriano, Vicente
AU  - Soriano V
AUID- ORCID: 0000-0002-4624-5199
AD  - Health Sciences School & Medical Center, Universidad Internacional La Rioja 
      (UNIR), Madrid, Spain.
FAU - Moreno-Torres, Victor
AU  - Moreno-Torres V
AD  - Health Sciences School & Medical Center, Universidad Internacional La Rioja 
      (UNIR), Madrid, Spain.
AD  - Department of Internal Medicine, Puerta de Hierro University Hospital & Research 
      Institute, Majadahonda, Madrid, Spain.
FAU - Trevino, Ana
AU  - Trevino A
AD  - Health Sciences School & Medical Center, Universidad Internacional La Rioja 
      (UNIR), Madrid, Spain.
FAU - Barreiro, Pablo
AU  - Barreiro P
AD  - Health Sciences School & Medical Center, Universidad Internacional La Rioja 
      (UNIR), Madrid, Spain.
AD  - Infctious Diseases Unit, Emergency Hospital Enfermera Isabel Zendal, Madrid, 
      Spain.
FAU - de Jesus, Fernando
AU  - de Jesus F
AD  - Health Sciences School & Medical Center, Universidad Internacional La Rioja 
      (UNIR), Madrid, Spain.
FAU - Corral, Octavio
AU  - Corral O
AD  - Health Sciences School & Medical Center, Universidad Internacional La Rioja 
      (UNIR), Madrid, Spain.
FAU - de Mendoza, Carmen
AU  - de Mendoza C
AD  - Department of Internal Medicine, Puerta de Hierro University Hospital & Research 
      Institute, Majadahonda, Madrid, Spain.
LA  - eng
PT  - Journal Article
DEP - 20230427
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Antiviral Agents)
RN  - 0 (HIV Protease Inhibitors)
SB  - IM
MH  - Humans
MH  - Antiviral Agents/adverse effects
MH  - *HIV Infections/complications/drug therapy
MH  - *Coinfection/drug therapy/chemically induced
MH  - *Hepatitis C, Chronic/drug therapy
MH  - *Hepatitis C/complications/drug therapy/chemically induced
MH  - Hepacivirus
MH  - *Drug-Related Side Effects and Adverse Reactions
MH  - *HIV Protease Inhibitors
OTO - NOTNLM
OT  - HBV reactivation
OT  - HIV
OT  - Hepatitis C
OT  - antiretrovirals
OT  - coinfection
OT  - direct-acting antivirals
OT  - drug-drug interactions
OT  - side effects
EDAT- 2023/04/25 17:43
MHDA- 2023/04/25 17:44
CRDT- 2023/04/25 07:42
PHST- 2023/04/25 17:44 [medline]
PHST- 2023/04/25 17:43 [pubmed]
PHST- 2023/04/25 07:42 [entrez]
AID - 10.1080/14740338.2023.2206647 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2023 Jan-Jun;22(5):363-372. doi: 
      10.1080/14740338.2023.2206647. Epub 2023 Apr 27.